Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Aytu BioPharma, Inc. (AYTU)
NASDAQ:AMEX Investor Relations:
aytubio.com/investors/stock-information
Company Research
Source: Yahoo! Finance
Key Financial Results Revenue: US$81.0m (down 25% from FY 2023). Net loss: US$15.8m (loss narrowed by 7.1% from FY 2023). US$2.86 loss per share (improved from US$5.11 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Aytu BioPharma EPS Misses Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 15%. Looking ahead, revenue is expected to decline by 8.2% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 10%. The company's shares are down 3.7% from a week ago. Risk Analysis It is worth noting though that we have found 2 warning signs for Aytu BioPharma that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nat
Show less
Read more
Impact Snapshot
Event Time:
AYTU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AYTU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AYTU alerts
High impacting Aytu BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AYTU
News
- Attention Deficit Hyperactivity Disorder Market to hit USD 24.6 billion by 2032, says Global Market Insights Inc. [Yahoo! Finance]Yahoo! Finance
- Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma Disclosure Notification [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma Disclosure NotificationAccesswire
- Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) [Yahoo! Finance]Yahoo! Finance
AYTU
Sec Filings
- 12/4/24 - Form 8-K
- 11/13/24 - Form SC
- 11/13/24 - Form 10-Q
- AYTU's page on the SEC website